References
Aloke, C., Egwu, C. O., Aja, P. M., Obasi, N. A., Chukwu, A., Akumadu, B. O., Ogbu, P. N., & Achilonu, I. (2022). Current advances in the management of diabetes mellitus. Biomedicines, 10(10), 2436. https://doi.org/10.3390/biomedicines10102436
Ansari, M.J., Anwer, M.K., Jamil, S., Al-Shdefat, R., Ali, B.E., Ahmad, M.M., & Ansari, M.N. (2016). Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: Pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Delivery, 23(6), 1972–1979. https://doi.org/10.3109/10717544.2015.1039666
Bahman, F., Greish, K., & Taurin, S. (2019). Bioavailability and stability of anti-diabetic drugs: Challenges and advances. Journal of Pharmaceutical Sciences, 108(9), 1-13. https://doi.org/10.1002/jps.2324
Cao, X., Chen, N., & Li, Y. (2023). Editorial: Beta cell function and diabetes remission. Frontiers in Endocrinology, 14, 1298101. https://doi.org/10.3389/fendo.2023.1298101
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. I. (2018). IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271–281. https://doi.org/10.1016/j.diabres.2018.02.023
Chrvala, C. A., Sherr, D., & Lipman, R. D. (2016). Diabetes self-management education for adults with type 2 diabetes mellitus: A systematic review of the effect on glycemic control. Patient Education and Counseling, 99(6), 926–943. https://doi.org/10.1016/j.pec.2015.11.003
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., & Weiss, R. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1, 15019. https://doi.org/10.1038/nrdp.2015.19
Edelhauser, H. F., Wittmar, M., & Geiger, D. (2010). Nanoparticle-mediated drug delivery and its impact on the bioavailability and stability of therapeutic agents. Journal of Nanomedicine & Nanotechnology, 1(1), 15-24. https://doi.org/10.4172/2157-7439.1000103
Galindo, R. J., Trujillo, J. M., Low Wang, C. C., & McCoy, R. G. (2023). Advances in the management of type 2 diabetes in adults. BMJ Medicine, 2, e000372. https://doi.org/10.1136/bmjmed-2022-000372
Harvard T.H. Chan School of Public Health. (2023). Diabetes mellitus. Retrieved June 25, 2024, from https://www.hsph.harvard.edu/nutritionsource/disease-prevention/diabetes-prevention/
Hussain, M., & Chowdhury, M. (2019). Improving therapeutic outcomes of anti-diabetic medications: Role of bioavailability and stability. Diabetes Research and Clinical Practice, 156, 107834. https://doi.org/10.1016/j.diabres.2019.107834
International Diabetes Federation. (2024). IDF diabetes atlas (10th ed.). Retrieved June 25, 2024, from https://www.diabetesatlas.org
Ismail, M., & Csóka, I. (2017). Polymeric nanoparticles for drug delivery. Journal of Drug Delivery Science and Technology, 42, 57-67. https://doi.org/10.1016/j.jddst.2017.01.008
Kesharwani, P., Biswas, S., & Iyer, A. K. (2018). Nanotechnology in drug delivery systems. Molecular Pharmaceutics, 15(9), 3534-3546. https://doi.org/10.1021/acs.molpharmaceut.8b00581
Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A review on diabetes mellitus: Type 1 & type 2. World Journal of Pharmaceutical and Pharmaceutical Sciences, 9, 838–850.
Mansoor, T. A., Kondiah, P. P. D., Choonara, Y. E., & Pillay, V. (2019). Nanoparticle-based drug delivery systems for anti-diabetic drugs. Nanotechnology Reviews, 8(1), 123-140. https://doi.org/10.1515/ntrev-2019-0092
Menditto, E., Fabiano, A., & Ippolito, R. (2018). Stability testing of pharmaceuticals: New approaches. International Journal of Pharmaceutics, 548(1), 28-37. https://doi.org/10.1016/j.ijpharm.2018.07.054
Mishra, V., Bansal, K.K., Verma, A., Yadav, N., Thakur, S., Sudhakar, K., & Rosenholm, J.M. (2018). Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics, 10(4), 191. https://doi.org/10.3390/pharmaceutics10040191
Mohammadpour, F., Kamali, H., Gholami, L., McCloskey, A.P., Kesharwani, P., & Sahebkar, A. (2022). Solid lipid nanoparticles: A promising tool for insulin delivery. Expert Opinion on Drug Delivery, 19(11), 1577–1595. https://doi.org/10.1080/17425247.2022.2138328
Mohsen, A. A. (2019). Metabolism of oral anti-diabetic drugs and its implications on bioavailability. Diabetes Therapy, 10(6), 1877-1891. https://doi.org/10.1007/s12325-019-01063-w
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2009). Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 32(1), 193-203. https://doi.org/10.2337/dc08-9025
Nie, X., Chen, Z., Pang, L., Wang, L., Jiang, H., Chen, Y., Zhang, Z., Fu, C., Ren, B., & Zhang, J. (2020). Oral nano drug delivery systems for the treatment of type 2 diabetes mellitus: An available administration strategy for antidiabetic phytocompounds. International Journal of Nanomedicine, 15, 10215–10240. https://doi.org/10.2147/IJN.S285134
Nogueira, L. F., Ribeiro, R. A., & Lima, R. R. (2013). Glibenclamide as an anti-diabetic agent: Pharmacodynamics and clinical use. Journal of Pharmacology & Pharmacotherapeutics, 4(4), 276-283. https://doi.org/10.4103/0976-500X.120469
Okemah, J., Peng, J., & Quiñones, M. (2018). Addressing clinical inertia in type 2 diabetes mellitus: A review. Advances in Therapy, 35, 1735–1745. https://doi.org/10.1007/s12325-018-0819-5
Park, Y., & Dembele, T. A. (2022). Application of nanoparticles: Diagnosis, therapeutics, and delivery of insulin/anti-diabetic drugs to enhance the therapeutic efficacy of diabetes mellitus. Life, 12(12), 2078. https://doi.org/10.3390/life12122078
Sastri, K.T., Radha, G.V., Pidikiti, S., & Vajjhala, P. (2020). Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies. Journal of Applied Pharmaceutical Science, 10(1), 126–141. https://doi.org/10.7324/JAPS.2020.10617
Satake, T., Takai, K., Saito, S., & Shimasaki, H. (2002). The relationship between glycated hemoglobin and insulin sensitivity in diabetic patients. Diabetes Research and Clinical Practice, 57(2), 125-132. https://doi.org/10.1016/S0168-8227(02)00004-6
Satapathy, M.K., Yen, T.L., Jan, J.S., Tang, R.D., Wang, J.Y., Taliyan, R., Yang, C.H. (2021). Solid lipid nanoparticles (SLNs): An advanced drug delivery system targeting brain through BBB. Pharmaceutics, 13(8), 1183. https://doi.org/10.3390/pharmaceutics13081183
Selvaraj, R., Pillai, V. M., & Sreenivasan, K. (2017). Nanoparticle-based drug delivery systems: A new frontier in drug formulation. Advanced Drug Delivery Reviews, 118, 97-108. https://doi.org/10.1016/j.addr.2017.08.004
Souto, E. B., & Silva, A. A. (2011). Nanocarriers for improving the bioavailability of poorly water-soluble anti-diabetic drugs. Nanomedicine: Nanotechnology, Biology, and Medicine, 7(6), 1-15. https://doi.org/10.1016/j.nano.2011.10.012
Souto, E. B., Lima, M. P., & Schapoval, E. E. (2011). Bioavailability and stability of oral anti-diabetic drugs: Challenges and solutions. European Journal of Pharmaceutical Sciences, 43(3), 137-149. https://doi.org/10.1016/j.ejps.2011.02.014
Sultana, A., Zare, M., Thomas, V., Kumar, T.S.S., & Ramakrishna, S. (2022). Nano-based drug delivery systems: Conventional drug delivery routes, recent developments, and future prospects. Medical Drug Discovery, 15, 100134. https://doi.org/10.1016/j.medidd.2022.100134
Surendiran, G., Sundaram, V., & Prabakaran, M. (2009). Lipid-based nanoparticles for controlled drug delivery. Journal of Applied Pharmaceutical Science, 1(5), 30-35. https://doi.org/10.7324/JAPS.2009.155
Unnikrishnan, R., Anjana, R. M., & Mohan, V. (2016). Diabetes mellitus and its complications in India. Nature Reviews Endocrinology, 12, 357–370. https://doi.org/10.1038/nrendo.2016.53
Veiseh, O., Sun, T., Zhang, M., & Bhattarai, N. (2015). Cancer nanomedicine: From targeted therapy to combination therapy. Trends in Molecular Medicine, 21(4), 223-232. https://doi.org/10.1016/j.molmed.2015.02.001
Vieira, C. S., Ferreira, D. R., & Silva, D. S. (2019). Improving bioavailability and stability of anti-diabetic drugs: Advances in drug delivery systems. International Journal of Nanomedicine, 14, 5083-5099. https://doi.org/10.2147/IJN.S221520
Wang, M., Wang, C., Ren, S., Pan, J., Wang, Y., Shen, Y., Zeng, Z., Cui, H., & Zhao, X. (2022). Versatile oral insulin delivery nano systems: From materials to nanostructures. International Journal of Molecular Sciences, 23(6), 3362. https://doi.org/10.3390/ijms23063362
Welengodage, I., & Katuwavila, N.P. (2024). Recent advancements in lipid nanoparticle technology for oral insulin delivery. University of Colombo Review, 5(1), 130–144. https://doi.org/10.4038/ucr.v5i1.134
Wong, T. P., Al-Salami, H., & Dass, C. R. (2017). Enhancing bioavailability and stability of anti-diabetic drugs using nanoparticle-based delivery systems. International Journal of Pharmaceutics, 525(1-2), 68-82. https://doi.org/10.1016/j.ijpharm.2017.03.017
World Health Organization (WHO). (2018). Diabetes. Retrieved from https://www.who.int/news-room/fact-sheets/detail/diabetes
World Health Organization. (2023). Global report on diabetes. Retrieved June 24, 2024, from https://www.who.int/news-room/fact-sheets/detail/diabetes
Yeung, C. K., Law, W. K., & Choi, H. M. (2019). Metformin in the management of type 2 diabetes: A review of the clinical evidence. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(4), 2081-2092. https://doi.org/10.1016/j.dsx.2019.04.032